Grassley Urges Administration to Fix Misclassification of EpiPen, Other Drugs Under Medicaid Drug Rebate Program
For months, Sen.
"I'm very interested in the executive order. The Administration is right to focus on the high cost of prescription drugs. The sticker shock is real. It affects people paying out of pocket, and it affects spending by Medicaid and Medicare. One step the Administration could and should take immediately is to make sure all prescription drugs are classified the right way under the Medicaid Drug Rebate Program. Billions of dollars owed to the taxpayers are at stake. We're all worried about health care spending and trying to get the most bang for the buck. Holding prescription drug companies accountable for their obligations to taxpayers is a good place to start. It's unclear why the previous administration apparently let Mylan get by for years with over-charging for EpiPens, and apparently other companies with their drugs, but there's a chance now to fix that mistake. The current administration should do it."
Grassley's letter to then-President-elect Trump urging appropriate classification under the Medicaid Drug Rebate Program is available here http://www.grassley.senate.gov/sites/default/files/constituents/2016-12-12%20CEG%20to%20Trump%20%28Drug%20Pricing%20and%20Competition%29.pdf. Grassley's January letter to the outgoing administration on the issue is available here https://www.grassley.senate.gov/sites/default/files/constituents/2017-01-04%20CEG%20to%20CMS%20%28Drug%20Misclassifications%29..pdf. His
Read this original document at: https://www.grassley.senate.gov/news/news-releases/grassley-urges-administration-fix-misclassification-epipen-other-drugs-under


HHS Secretary Price To Durbin: I Have Not Seen Senate Republicans’ Plan To Repeal Health Care
ISAKSON HIGHLIGHTS CHOICE, APPEALS REFORMS AS CRITICAL VA PRIORITIES
Advisor News
- Survey: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- States push short-term insurance as healthcare costs climb
- WYDEN, SANDERS, SENATE DEMOCRATS CALL OUT INSURANCE COMPANY COLLUSION WITH TRUMP ADMINISTRATION TO KICK THOUSANDS OF AMERICANS OFF HEALTH INSURANCE
- WYDEN STATEMENT ON FINANCE COMMITTEE DEMOCRATIC MAJORITY AGENDA
- Health insurance switch costs city
- New LTC solutions fill a critical gap for clients
More Health/Employee Benefits NewsLife Insurance News
- AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
- AM Best Affirms Credit Ratings of NongHyup Property and Casualty Insurance Company Limited
- AM Best Affirms Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries; Upgrades Issuer Credit Rating of Standard Security Life Insurance Company of New York
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- Nebraska widow’s big win against life insurer in legal limbo
More Life Insurance News